Article may be outdated

This article is 5 days old. Some details may have changed since publication.

Wired·3 min read·medium

Synchron Pauses Trials of Its Brain Implant Due to Performance Issues

E
Emily Mullin
Synchron Pauses Trials of Its Brain Implant Due to Performance Issues
✦AI Summary

Brain-computer interface startup Synchron has paused enrollment in its clinical trials due to performance issues with the lead cable in its second-generation Stentrode device. The company is currently undergoing restructuring while it works to resolve the technical flaw.

Why it matters

As a competitor to Neuralink, Synchron's technical setbacks highlight the significant challenges in developing safe and reliable brain-implant technology.

✦Dive DeeperCreate a free account to unlock

The Brooklyn-based startup, a competitor to Elon Musk’s Neuralink, is also undergoing a restructuring, which includes eliminating jobs and scaling back its footprint in New York while building up a team in San Diego to support the development of an entirely new device.

Synchron is one of several companies developing brain-computer interface technology meant to allow people to control digital devices by reading brain signals and translating those signals into output commands. The company has touted its technology, dubbed the Stentrode, as minimally invasive since it does not rest in the brain itself or require brain surgery.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
technologyhealthstartups
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in